Whipple disease and arthritis

Authors
Citation
X. Puechal, Whipple disease and arthritis, CURR OP RH, 13(1), 2001, pp. 74-79
Citations number
64
Categorie Soggetti
Rheumatology
Journal title
CURRENT OPINION IN RHEUMATOLOGY
ISSN journal
10408711 → ACNP
Volume
13
Issue
1
Year of publication
2001
Pages
74 - 79
Database
ISI
SICI code
1040-8711(200101)13:1<74:WDAA>2.0.ZU;2-6
Abstract
Whipple disease is a chronic, multisystem, curable, bacterial infection tha t usually affects middle-aged men and has a wide range of clinical manifest ations. The most common symptoms are weight loss and diarrhea, preceded in three quarters of cases by arthritis for a mean of 6 years. In most patient s, periodic acid-Schiff staining of proximal small bowel biopsy specimens r eveals inclusions within the macrophages, corresponding to bacterial struct ures. However, patients with various manifestations of the disease may have no gastrointestinal symptoms and negative jejunum biopsy results. Before t he onset of gastrointestinal symptoms, a strong index of clinical suspicion is the key to diagnosis. The classic setting is longterm, unexplained, ser onegative oligoarthritis or polyarthritis with a palindromic or relapsing c ourse, although chronic destructive polyarthritis and spondyloarthropathy h ave been repeatedly reported. Identification of the Whipple bacterium, Trop heryma whippelii, has led to the development of polymerase chain reaction a s a diagnostic tool in patients in the early stages of the disease or with atypical Whipple disease. This technique can be used to detect the bacteriu m in many tissues and fluids, including synovial tissue and fluid. The rece nt cultivation of the Whipple bacillus should lead to the development of se rologic tests, further facilitating diagnosis. These recent major advances may show that the infection is more frequent than previously suspected and may expand the clinical spectrum of the disease. It may also allow earlier diagnosis, thereby preventing the development of the severe systemic and so metimes fatal forms of the disease. Curr Opin Rheumatol 2001, 13:74-79 (C) 2001 Lippincott Williams & Wilkins, Inc.